Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles.
IL-6 receptor signaling
chemokine
extracellular vesicles
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
24 05 2020
24 05 2020
Historique:
received:
28
04
2020
revised:
20
05
2020
accepted:
20
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
25
2
2021
Statut:
epublish
Résumé
Interleukin-6 (IL-6) signaling is a crucial regulatory event important for many biological functions, such as inflammation and tissue regeneration. Accordingly, several pathological conditions are associated with dysregulated IL-6 activity, making it an attractive therapeutic target. For instance, blockade of IL-6 or its α-receptor (IL-6R) by monoclonal antibodies has been successfully used to treat rheumatoid arthritis. However, based on different signaling modes, IL-6 function varies between pro- and anti-inflammatory activity, which is critical for therapeutic intervention. So far, three modes of IL-6 signaling have been described, the classic anti-inflammatory signaling, as well as pro-inflammatory trans-signaling, and trans-presentation. The IL-6/IL-6R complex requires an additional β-receptor (gp130), which is expressed on almost all cells of the human body, to induce STAT3 (signal transducer and activator of signal transcription 3) phosphorylation and subsequent transcriptional regulation. In contrast, the IL-6R is expressed on a limited number of cells, including hepatocytes and immune cells. However, the proteolytic release of the IL-6R enables trans-signaling on cells expressing gp130 only. Here, we demonstrate a fourth possibility of IL-6 signaling that we termed
Identifiants
pubmed: 32456348
pii: cells9051307
doi: 10.3390/cells9051307
pmc: PMC7291149
pii:
doi:
Substances chimiques
Receptors, Interleukin-6
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Biol Chem. 2015 Oct 23;290(43):26059-71
pubmed: 26359498
J Immunol Res. 2014;2014:149185
pubmed: 24901008
Curr Opin Immunol. 2015 Jun;34:75-82
pubmed: 25749511
Proteomes. 2019 Apr 11;7(2):
pubmed: 30979041
PLoS Biol. 2017 Jan 6;15(1):e2000080
pubmed: 28060820
FASEB J. 2015 Aug;29(8):3549-57
pubmed: 25957281
J Virol. 2014 Oct;88(19):11529-39
pubmed: 25056899
Sci Rep. 2017 Mar 09;7:44053
pubmed: 28276471
Adv Protein Chem Struct Biol. 2019;116:283-309
pubmed: 31036294
J Biol Chem. 2013 May 24;288(21):14756-68
pubmed: 23564454
Rheumatology (Oxford). 2020 Feb 1;59(2):292-302
pubmed: 31312844
Wien Med Wochenschr. 2015 Jan;165(1-2):14-22
pubmed: 25335457
J Thromb Haemost. 2014 Jul;12(7):1182-92
pubmed: 24818656
J Cell Sci. 2019 May 31;132(11):
pubmed: 31076514
Nat Rev Dis Primers. 2016 Jun 30;2:16045
pubmed: 28117397
Eur J Immunol. 1993 Feb;23(2):473-80
pubmed: 8436181
Nat Immunol. 2017 Jan;18(1):74-85
pubmed: 27893700
Cytokine Growth Factor Rev. 2015 Oct;26(5):475-87
pubmed: 26189695
Biochim Biophys Acta. 2016 Nov;1863(11):2795-2808
pubmed: 27599715
J Immunol. 2013 Dec 1;191(11):5383-97
pubmed: 24140643
Eur J Biochem. 2001 Jan;268(1):160-7
pubmed: 11121117
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Retrovirology. 2014 May 30;11:42
pubmed: 24884925
J Immunol. 2016 Nov 1;197(9):3705-3715
pubmed: 27698010
Ann Rheum Dis. 2013 Apr;72(4):482-92
pubmed: 23172750
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11924-8
pubmed: 8265649
J Biol Chem. 2010 Nov 26;285(48):37531-41
pubmed: 20876574
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
Clin Pharmacol Ther. 2017 Oct;102(4):591-598
pubmed: 28675418
Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S46-53
pubmed: 26120866
Nat Commun. 2018 Jan 15;9(1):191
pubmed: 29335551
Br J Haematol. 2019 Jan;184(2):232-241
pubmed: 30203839
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Trends Cell Biol. 2015 Jun;25(6):364-72
pubmed: 25683921
Commun Biol. 2019 Jan 18;2:27
pubmed: 30675525
J Biol Chem. 2011 Dec 16;286(50):42959-70
pubmed: 21990364
Sci Rep. 2016 May 06;6:25550
pubmed: 27151651
Mod Rheumatol. 2020 Mar;30(2):239-248
pubmed: 31268376
Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E411-E420
pubmed: 31237452
EMBO J. 2019 Oct 15;38(20):e101266
pubmed: 31544965
Immunity. 2019 Apr 16;50(4):812-831
pubmed: 30995501
Cancer Lett. 2019 Aug 1;456:69-79
pubmed: 31055110
J Biol Chem. 2015 Feb 20;290(8):4545-51
pubmed: 25568317
J Clin Invest. 2000 Oct;106(7):887-95
pubmed: 11018077
J Immunol. 1997 Aug 1;159(3):1474-81
pubmed: 9233646
Pharmacogenomics J. 2019 Aug;19(4):368-374
pubmed: 30647443
Mol Cancer. 2019 Mar 18;18(1):42
pubmed: 30885232
Nat Biotechnol. 1997 Feb;15(2):142-5
pubmed: 9035138
J Clin Oncol. 2012 Mar 20;30(9):1005-14
pubmed: 22355058
RMD Open. 2019 Aug 1;5(2):e000887
pubmed: 31452928